EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date

Gretchen MacCarrick, Swaroop Aradhya, Mitch Bailey, Dorna Chu, Abigail Hunt, Emanuela Izzo, Deborah Krakow iD, William Mackenzie, Sarah Poll, Cathleen Raggio, Renée Shediac, Klane K White und 2 weitere

American Journal of Medical Genetics Part A · 2024

DOI: 10.1002/ajmg.a.63646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2024. Verfasst von Gretchen MacCarrick und 13 weiteren Autor:innen. Beteiligte Einrichtung: McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Genetic Testing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BioMarin Pharmaceutical Inc, BioMarin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular genetics enables more precise diagnoses of skeletal dysplasia and other skeletal disorders (SDs). We investigated the clinical utility of multigene panel testing for 5011 unrelated individuals with SD in the United States (December 2019–April 2022). Median (range) age was 8 (0–90) years, 70.5% had short stature and/or disproportionate growth, 27.4% had a positive molecular diagnosis (MDx), and 30 individuals received two MDx. Genes most commonly contributing to MDx were FGFR3 (16.9%), ALPL (13.0%), and COL1A1 (10.3%). Most of the 112 genes associated with ≥1 MDx were primarily involved in signal transduction ( n = 35), metabolism ( n = 23), or extracellular matrix organization ( n = 17). There were implications associated with specific care/treatment options for 84.4% (1158/1372) of MDx‐positive individuals; >50% were linked to conditions with targeted therapy approved or in clinical development, including osteogenesis imperfecta, achondroplasia, hypophosphatasia, and mucopolysaccharidosis. Forty individuals with initially inconclusive results became MDx‐positive following family testing. Follow‐up mucopolysaccharidosis enzyme activity testing was positive in 14 individuals (10 of these were not MDx‐positive). Our findings showed that inclusion of metabolic genes associated with SD increased the clinical utility of a gene panel and confirmed that integrated use of comprehensive gene panel testing with orthogonal testing reduced the burden of inconclusive results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingHumansChildChild, PreschoolAdolescentMaleFemaleInfantAdultInfant, NewbornMiddle AgedYoung AdultAgedAged, 80 and overBone Diseases, DevelopmentalReceptor, Fibroblast Growth Factor, Type 3Osteogenesis ImperfectaCohort Studies

Stichwörter der Autor:innen

gene panelgenetic diagnosticsgenetic testingosteochondrodysplasiasskeletal disordersskeletal dysplasia

Substanzen

Receptor, Fibroblast Growth Factor, Type 3

Autor:innen und Institutionen

  • McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Invitae Corporation, San Francisco, California, USA.
  • BioMarin Pharmaceutical Inc, Novato, California, USA.
  • David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Department of Orthopaedic Surgery, Nemours Children's Hospital, Wilmington, Delaware, USA.
  • Department of Orthopedic Surgery, Hospital for Special Surgery, New York, New York, USA.

ORCID-Profile: Deborah Krakow

Förderung

  • BioMarin Pharmaceutical Inc
  • BioMarin Pharmaceutical

Zitieren

APA

MacCarrick, G., Aradhya, S., Bailey, M., Chu, D., Hunt, A., Izzo, E., Krakow, D., Mackenzie, W., Poll, S., Raggio, C., Shediac, R., White, K. K., McLaughlin, H. M., & Seratti, G. (2024). Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63646

Vancouver

MacCarrick G, Aradhya S, Bailey M, Chu D, Hunt A, Izzo E, et al. Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date. American Journal of Medical Genetics Part A. 2024. doi:10.1002/ajmg.a.63646

BibTeX
@article{MacCarrick2024,
  author = {MacCarrick, Gretchen and Aradhya, Swaroop and Bailey, Mitch and Chu, Dorna and Hunt, Abigail and Izzo, Emanuela and Krakow, Deborah and Mackenzie, William and Poll, Sarah and Raggio, Cathleen and Shediac, Renée and White, Klane K and McLaughlin, Heather M and Seratti, Guillermo},
  title = {Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date},
  journal = {American Journal of Medical Genetics Part A},
  year = {2024},
  doi = {10.1002/ajmg.a.63646}
}
Kostenlos starten →